NCT04601181Unknown1 期
A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD22 in Patients With Refractory or Relapsed B Cell Malignancies
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- The incidence of AE or SAE of CART cell infusion in relation to the study drug at grade ≥3 (refer to CTCAE version 4.03);
研究概览
简要总结
This is a single-center, nonrandomized, open-label, study to evaluate the safety and clinical activity of allogeneic CAR-T targeting CD22 in patients with refractory or relapsed CD22-positive B cell malignancies
详细描述
The patients will receive infusion of ThisCART22 cells from health donor ,to evaluate the safety and efficacy of ThisCART22 Cells in patients with refractory or relapsed CD22-positive B cell malignancies.
In this study, the dose range is 0.2-60 x10^6 cells per kg body weight (no more than 3.0 x 10^9 in total).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who volunteered to participate in the research and signed a written informed consent;
- •The informed consent was signed between the ages of 3-70, regardless of gender or race;
- •CD22 positive hematologic malignancies with no alternative treatment options deemed by investigator. including those who are not eligible for allogeneic stem cell transplantation (SCT) due to the following reasons： 3.1 age； 3.2 Concurrent disease； 3.3 Other contraindications, such as contraindications to total body irradiation (TBI) (TBI is one of the important treatment measures before allogeneic stem cell transplantation of ALL)； 3.4 Lack of suitable donors； 3.5 Patients with relapse after CD19-CAR T treatment；
- •Estimated life expectancy > 12 weeks deemed by investigator
- •Recurrence after any stem cell transplantation (regardless of previous treatment regimen);
- •Patients who relapse after previous allogeneic SCT (myeloablative or non-myeloablative) and meet all the following entry criteria:
- •6.1 No active GVHD and no immunosuppression is required； 6.2 Transplant for more than 4 months；
- •Serum creatinine ≤1.6 mg/dl and/or BUN ≤ 1.5 mg/dl；
- •Serum ALT/ AST < 5 upper limit of normal (ULN)；
- •Measurable or detectable disease at time of enrollment，include minimal residual disease (MRD) detected by immunotyping, cytogenetics or PCR.
- •Cardiac ejection fraction ≥ 40%.
- •Eastern cooperative oncology group (ECOG) performance status of ≤
- •Female subjects with fertility have a negative pregnancy test result within 48 hours before the infusion and are not breast-feeding; all subjects with fertility potential before being enrolled in the study and throughout the study period until the last infusion Within 3 months, take adequate contraceptive measures.
排除标准
- •Pregnant or lactating women;
- •Participated in another clinical trial during the first 4 weeks of the enrolled study or intended to participate in another clinical trial throughout the study period;
- •Have been treated with any gene product;
- •Uncontrolled infection;
- •History of HIV infection;
- •Active hepatitis B virus or hepatitis C virus infection;
- •Systemic steroid therapy may be required for cell infusion or collection, or there may be conditions that the investigator considers may require steroid therapy during blood collection or infusion.Corticosteroids for disease treatment are permitted, and inhaled steroids or hydrocortisone physiologic replacement therapy for patients with adrenocortical dysfunction is permitted beyond the time of cell collection or infusion;
- •Patients with grade 2-4 GVHD, or deemed need to manage by investigator;
- •The presence of GVHD under treatment;.
- •Patients with active CNS involvement by malignancy;
- •Patients combine with other disease cause neutrophil count (ANC) <750/uL or PLT< 50,000/uL
- •The researchers considered the subjects unsuitable for this clinical trial for various reasons.
结局指标
主要结局
The incidence of AE or SAE of CART cell infusion in relation to the study drug at grade ≥3 (refer to CTCAE version 4.03);
时间窗: From infusion to week 12
ORR (sum of CR and CRi) after infusion.
时间窗: From infusion to week 12
次要结局
- ORR at week 4, 8, and 24 after infusion (ORR4, ORR8, ORR24).(At week 4, 8, and 24 after infusion)
- The survival time of CAR-T-22 cells in vivo;(From infusion to month 12)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Clinical Study to Evaluate the Safety and Efficacy of Candela TechnologyHair ReductionTattoo RemovalWrinkleScarsBenign Cutaneous Vascular LesionsSkin ConditionsAcneNCT06202274Candela Corporation500
招募中
1 期
Study Of B7H3 CAR-T Cells in Treating Advanced Liver CancerHepatocellular CarcinomaNCT05323201The Affiliated Hospital of Xuzhou Medical University15
已完成
3 期
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive AspergillusInvasive CandidiasisInvasive AspergillosisNCT05707832CSPC Ouyi Pharmaceutical Co., Ltd.31
Unknown
早期 1 期
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver CancerAdvanced Primary Liver CancerNCT05411757Shandong Public Health Clinical Center12
进行中（未招募）
1 期
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT06114056West China Hospital3